Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768433 | 1.00 | EPHX1 (0.57) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1768694 | 0.98 | EPHX1 (0.54) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1768691 | 0.98 | EPHX1 (0.54) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL13585343 | 0.92 | EPHX2 (0.45) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL13585340 | 0.92 | EPHX2 (0.45) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL13585537 | 0.85 | EPHX1 (0.49) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL13585539 | 0.85 | EPHX1 (0.49) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1345188 | 0.85 | SMN1; SMN2 (0.43) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1768775 | 0.84 | EPHX1 (0.63) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL1768784 | 0.84 | EPHX1 (0.63) | EPHX1KDM4EALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102712676-B | There is the peptidomimetic that the template of CCR10 antagonistic activity is fixing | 波利弗尔股份公司 | 2016-10-26 | — | — | CN | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | EPHX1 2469/4885KDM4E 4722/4885ALDH1A1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.